Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Now Rated “Hold” by Wall Street Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus recommendation of “Hold” from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $21.44.

Several equities research analysts recently issued reports on NTLA shares. Citizens Jmp reissued a “market outperform” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. Barclays initiated coverage on Intellia Therapeutics in a research note on Tuesday, October 6th. They issued an “underweight” rating and a $8.00 price target for the company. Finally, Wall Street Zen lowered Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, offering a constructive counterpoint to the lower earnings forecasts. Analyst estimates
• Neutral Sentiment: Intellia plans to present at the Jefferies Global Healthcare Conference in London; the announcement did not include new clinical or financial information. Conference announcement
• Neutral Sentiment: A short-interest report claims a significant increase but lists short interest as zero shares, making the data internally inconsistent and difficult to interpret.
• Neutral Sentiment: The company reported inducement equity grants for new employees; the announcement provides no material business or clinical update. Inducement grants announcement
• Negative Sentiment: Analysts lowered projected earnings across multiple periods. The cuts reinforce concerns about Intellia’s expected losses and longer-term profitability, which may weigh on investor sentiment. Analyst estimates

Insider Activity

In other news, CEO John M. Leonard sold 9,000 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the completion of the transaction, the chief executive officer owned 1,138,064 shares in the company, valued at approximately $13,645,387.36. The trade was a 0.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is owned by insiders.

Institutional Trading of Intellia Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its holdings in shares of Intellia Therapeutics by 11.2% in the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after acquiring an additional 139,325 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Intellia Therapeutics by 1,082.1% during the 1st quarter. Royal Bank of Canada now owns 465,499 shares of the company’s stock worth $5,968,000 after purchasing an additional 426,121 shares during the period. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $1,595,000. Assenagon Asset Management S.A. bought a new position in Intellia Therapeutics during the 3rd quarter valued at about $3,875,000. Finally, BlackRock Inc. bought a new position in Intellia Therapeutics during the 2nd quarter valued at about $260,721,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Trading Down 7.8%

Shares of NASDAQ NTLA opened at $11.17 on Wednesday. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -3.33 and a beta of 1.83. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $18.48. The firm has a 50 day moving average of $12.05 and a 200 day moving average of $13.02.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 5th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Intellia Therapeutics had a negative return on equity of 64.74% and a negative net margin of 805.75%. The company had revenue of $7.16 million during the quarter, compared to the consensus estimate of $9.74 million. During the same period in the prior year, the business posted ($0.92) earnings per share. Intellia Therapeutics’s revenue for the quarter was down 47.8% compared to the same quarter last year. Sell-side analysts predict that Intellia Therapeutics will post -3.28 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.